In terms of those who hold wealth and those who create wealth, an interesting metamorphosis is currently underway.

  • First, wealth is changing hands as it gets transferred from the older generation to the new generation.
  • Second, sources of wealth creation are changing as new-age tech entrepreneurs and even corporate personnel, armed with employee stock options (ESOPs), have created wealth.
  • Thirdly, an increasing number of people from diverse backgrounds and with varying perspectives about wealth, join the ranks of the wealthy.

It is important to note that because of all these changes, the ability to take risks by wealthy and sophisticated investors has gone up significantly in the recent past.

Correspondingly, the investment landscape has also undergone some modifications and inclusions. Traditional investment avenues which do not generate positive real returns are being replaced with innovative solutions, which are to the further right of the risk-return spectrum. In the backdrop of such an environment, ultra high net worth (UHNW) investors are looking for new avenues to both preserve as well as grow their wealth.

Here are five emerging avenues that such investors can consider include:

Equity-linked Market Linked Debentures (MLDs) and Non-convertible Debentures (NCDs)

MLDs are usually issued by non-banking finance companies (NBFCs) and offer returns that are linked to specified equity indices based on an underlying condition. For example, a 30-month MLD would pay the investor a predefined internal rate of return at the end of the tenure if Nifty 50 Index does not fall by more than 75%.

Proceeds from MLDs have a tax advantage compared with regular debt instruments but also have issuer risk as repayment of principal and defined IRR is at the end of the tenure. On the other hand, lower rated NCDs are debt products that offer higher interest rates than common debt instruments with the option of having regular coupon payments. These avenues are high in terms of risk and return as opposed to conventional debt instruments.

Additionally, both these products are rated by credit rating agencies and hence, can give investors a clear idea of the amount of risk involved. It must be noted that the options in the secondary debt market have increased significantly and while a lot of money goes into direct secondary debt portfolios made up of a mix of highly rated secondary bonds or deposits a small portion is also being used to increase portfolio returns through calculated decisions of investing in higher risk fintech companies that are backed by strong investors.

Venture Debt

While equity participation in early and growth stage unlisted companies is known to all, one more avenue is venture debt which refers to providing short-term loans (18 to 24 months) to established early and growth stage venture capital backed companies. Venture debt is underrepresented in investor portfolios in India and provides a healthy mix of high yield, regular coupons and equity participation through warrants.

In India, venture debt funds that provide investors an option to participate in this debt financing option are fast gaining momentum. According to data from private company tracker Venture Intelligence, the total amount raised by venture debt funds through private equity and venture capital debt funds jumped from $62 million in FY 2019-20 to $85 million in FY 2020-21.

Private Equity

Over the last decade, private equity and venture capital has metamorphosed from a nascent alternative asset class to a mature ecosystem. As a result, in the year 2019, private equity and venture capital investments in India grew to USD 48 billion or 1.7% of gross domestic product (GDP).

Buoyed by a thriving start-up ecosystem and strong exits, private equity is becoming an attractive investment option for an increasing number of UHNIs. The rally in the markets as also the immense money being made by the start-up founders and promoters has created an appetite for early-stage investing ideas or even ideas in listed companies targeting new sectors.

As a result, UHNW investors are looking to invest for the future whether in the unlisted or the listed space to reap benefits in the long run. They are interested in futuristic themes such as consumer tech, retail fintech, renewable energy, electric vehicles and associated components.

International Investing

In addition to asset class diversification, it has now become equally important to achieve geographical diversification. As a result, international investing is beginning to assume a key role in sophisticated investor portfolios.

Firstly, there is the potential to invest in innovative global companies that are currently not listed in India but have a place in the consumption basket of India. Secondly, investors can enhance the risk-adjusted returns of their portfolio by generating higher returns while reducing overall portfolio risk through diversification. And, thirdly, investors who have liabilities in a foreign currency can hedge the risk of rupee depreciation through exposure to international investments.

Indians can invest in international markets either through international mutual funds or directly under the Liberalised Remittance Scheme (LRS) of the Reserve Bank of India (RBI) that allows resident individuals to remit $250,000 during a financial year outside for the purpose of investment. Interesting options are also available now via direct stock investing internationally into US stock exchanges, where one can invest either into growth stocks directly or indirectly participate in new opportunities like a Bitcoin ETF or a new listing on the day of the IPO.

Real Estate Investment Trusts (REITs)

Traditionally, real estate has been a significant part of high net worth individuals (HNI) portfolios. However, due to the illiquid nature of real estate and the fluctuating real estate market, there has been a clear shift towards reducing real estate exposure. This does not mean that real estate no longer holds sway. What it means is that HNIs are now gaining real estate exposure through instruments like into Real Estate Investment Trusts (REITs). These are investment companies that either directly own real estate or have a share in the income of real estate properties. Thus, HNIs can gain the relevant real estate exposure by investing in REITs.

Bottom Line

We live in an era where innovation is enabling investors to create optimal investment portfolios that can meaningfully straddle their risk-return requirements. In these exuberant times, increasingly the concept of core “asset allocation-based” portfolios, which are stable and managed for the long-term, balanced alongside “tactical portfolios”, where profits booked can be put into well-thought-out investment opportunities, seems to be the flavor of the sophisticated investors mindset.

Finally, it must also be noted that UHNW clients are also increasingly interested in ensuring their investment portfolios are protected and optimized through professional legacy planning and tax planning.

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not offer financial advice, advisory or brokerage services, nor do we recommend or advise individuals or to buy or sell particular stocks or securities. Performance information may have changed since the time of publication. Past performance is not indicative of future results.

Forbes Advisor adheres to strict editorial integrity standards. To the best of our knowledge, all content is accurate as of the date posted, though offers contained herein may no longer be available. The opinions expressed are the author’s alone and have not been provided, approved, or otherwise endorsed by our partners.

Leave a comment

Vijay Gomatam

Consultant – Investment Banking

Vijay Gomatam has over 20 years of banking experience across M&A, corporate finance, capital markets, and corporate banking, with a strong focus on cross-border deal origination and execution across India, Southeast Asia, Japan, and Australia. He has deep sector expertise in industrials, IT services, media, and telecom, with extensive experience in India - Southeast Asia and India–Japan transactions. Vijay previously served as Director at MUFG Bank, Singapore, where he led the India - Japan M&A corridor, and earlier worked with Deutsche Bank, Merrill Lynch, Houlihan Lokey, and Edelweiss Alternative Asset Advisors.

His transaction experience includes Motherson Group’s acquisition of TSE-listed Yachiyo Industries, Takahata India’s stake sale to SPRL, Toppan Form’s acquisition of PT RDS in Indonesia, Mitsui’s investment in FKS Food & Agri, CVC’s investment in PT LinkNet, and capital market transactions for Southeast Asian media and telecom clients including SingTel, Axiata, and Bakrie Group.

He holds an MBA from IIM Calcutta and a B.E. (Hons.) from Nanyang Technological University, Singapore.

Akbar Khan

Senior Advisor – Investment Banking

Akbar Khan has over twenty years of experience across M&A advisory, Private Equity, and Corporate M&A, along with a decade as an entrepreneur and operator. He has held senior roles at Bank of America Merrill Lynch in India and London, where he led Telecom & Technology Investment Banking, Private Equity coverage, and M&A, and at General Electric, where he served as Head of Corporate Development and M&A for India and the MENA region. He has advised global corporates and financial sponsors including Reuters Plc, Telecom Italia, Hellenic Telecom, MTN, Tata Group, Apax Partners, Warburg Pincus, and TA Associates, and has led several notable transactions. These include advising E2E Networks on

its USD 50M capital raise, QuEST Global on its USD 75M Series B private placement to Warburg Pincus, Rain Technologies on its USD 65M Series A financing from QED Investors and Invus, Augnito.ai on its Pre-Series A raise from Apollo Hospitals Group, Tata Consultancy Services on the acquisition of Citigroup’s captive back-office unit, Forthnet in Greece on the acquisition of Netmed, and Telecom Italia on the sale of Cosmote via a leveraged buyout by Apax Partners and TPG.

In addition, Akbar co-founded and served as CEO of Rain Technologies India an earned wage access fintech platform.

He holds an MBA from London Business School and is a UK-qualified Chartered Accountant.

Shreyan ML

Managing Director – Healthcare & Pharma

Shreyan ML leads the healthcare and pharma investment banking practice and brings over 15 years of experience across investment banking, corporate M&A, and management consulting within the pharmaceutical sector. Prior to joining MAPE, he worked with Spark Capital, Strides Group, Wanbury Limited, and Tata Strategic Management Group.

His deal experience includes advising Curatio Healthcare on the sale of its business to Torrent Pharmaceuticals; Sale of TTK’s human pharma business to Bharat Serums; Glenmark Pharmaceuticals on the sale of the Razel brand to KKR-backed JB Chemicals & Pharma and the sale of nine dermatology brands to Eris Oaknet.

As Corporate M&A Head at Strides Group, he was involved in thesale of Agila to Mylan and led the animal health strategy at Sequent Scientific, executing over 12 transactions including fundraises and cross-border acquisitions.

He holds an MBA from IIM Indore and is a computer engineer from NIT Karnataka.

Arjun Mukherjee

Managing Director – Investment Banking

Arjun Mukherjee brings over 20 years of investment banking experience, with a strong focus on mergers & acquisitions and capital raising across Industrials, Education, Telecom, Cement, and Healthcare sectors. Prior to joining InCred Capital, he was part of the senior leadership team at MAPE Advisory Group for over a decade and has previously worked with Lazard, Ambit Capital, and Macquarie Capital.

His deal experience includes advising Veranda Learning on multiple acquisitions and its IPO, Emami on its bid for Paras Pharma, HeidelbergCement on the acquisitions of Mysore Cement and Indo Rama Cement, Italcementi on the acquisition of Sri Vishnu Cement along with an open offer, Bharti Airtel on the acquisitions of Hexacom India and the Spice Calcutta circle, as well as the sale of NLD rights to VSNL, Advent on its bid for Lafarge India.

He has also advised Jagdale Industries on the sale of its electrolyte drinks brand to Johnson & Johnson, promoters of Orissa Sponge on stake sales to Bhushan Steel and Monnet Ispat and on takeover defence, Fortis Healthcare on takeover defence and the sale of a minority stake to Khazanah, ICI India on the sale of its Nitrocellulose business to Actis and its rubber chemicals business, Jai Balaji Industries on the sale of its DI pipe unit and on QIP fund raising, Orbit Corporation and Ansal APIL on QIP-led equity fund raises, Walton Street Capital on raising a USD 500 million India-focused real estate fund, and on acquisition debt funding for the purchase of the RL Fine Chem API business.

Ashish Ambwani

Managing Director – Investment Banking

Ashish Ambwani has two decades of investment banking experience with a focus on cross-border M&A and Private Equity, and deep sector expertise across Consumption &Retail, Industrials and Digital businesses. He previously served as Director at Lazard for over 12 years and began his career at KPMG.

He has worked on numerous transactions including Osam Dairy’s sale to Dodla Dairy, Livpure’s capital raise from M&G Investments, QIMA’s acquisition of EFRAC Limited, Raymond Consumer Care’s FMCG sale to Godrej Consumer, IPO of Ethos Limited, Manohar Packaging’s sale to Parksons Packaging, MM Polytech’s sale to Huhtamaki, YY Inc.’s acquisition of Bigo, Kama Ayurveda’s fund raise and sale to Puig, Magnet360’s sale to Mindtree, Danone’s acquisition of Wockhardt nutrition assets, UCB’s sale of Indian brands to Dr Reddy’s, Sabero Organics’ sale to Coromandel, International Paper on its acquisition of AP Paper, Avantor on its acquisition of RFCL.

He holds an MBA from IIM Lucknow and a has a degree in Electrical & Electronics Engineering from NIT Trichy.

Jacob Mathew

Consultant- Investment Banking

Jacob Mathew brings over 25 years of experience in investment banking, private equity, and fundraising. He co-founded MAPE Advisory, a boutique investment bank focused on mid-market companies. Prior to MAPE, he was a Vice President (M&A) at Merrill Lynch India and played a key role in setting up the corporate finance practice at PwC India.

He has worked and led numerous transactions including the acquisition of Coats Viyella’s garment business by the AV Birla Group, the sale of Burnol and Coldarin brands, Dr Reddy’s buyout of American Remedies, and the sale of Diamond Dychem to Ciba AG. At MAPE, he led transactions across technology, telecommunications, consumer, healthcare, and retail sectors. His key clients include Coffee Day Enterprises, Strides, Igarashi Motors, J&J India, and Jyothi Labs.

He holds a PGDM from IIM Calcutta and is a Civil Engineer.

M Ramprasad

Consultant – Investment Banking

M Ramprasad has over 25 years of experience across investment banking, private equity, and fundraising. He co-founded MAPE Advisory, a boutique Indian investment bank focused on mid-market companies, which later merged with the Investment banking team at InCred in 2020. Prior to MAPE, he was a Senior Vice President at Merrill Lynch India, leading South India operations.

He has led marquee transactions for leading business groups including Tata Group, DuPont, ICICI Bank, Dr Reddy’s, and Sify, and at MAPE advised on landmark deals across manufacturing, infrastructure, and financial services. His key clients include Murugappa Group, ELGi Equipments, Curatio, Jyothi Labs, Karvy Financial Group, Star Health, and CRH Group.

He holds a PGDM from BIM Trichy and a degree in Chemistry.

Sanjay Singh

Head of Investment Banking – InCred Capital

Sanjay Singh is the Head of Investment Banking at InCred Capital, where he leads coverage across both advisory and equity capital markets. He brings over 20 years of experience across investment banking, strategy, and operations, with deep expertise in the pharmaceuticals and healthcare sectors.

Prior to joining InCred, he held leadership roles at BDA Partners as Head of India and Co-Head of Healthcare Asia, and at KPMG as Partner and Head of Life Sciences in India. He has also worked with Dr. Reddy’s Laboratories and Glenmark Pharmaceuticals.

His transaction experience includes advising Chemfield Cellulose on its divestment to Oji Holdings, Archimica S.p.A. on its acquisition by PI Industries, Synokem Pharmaceuticals on growth investment from TA Associates, Isagro SpA on the divestment of Isagro Asia Agrochemicals to PI Industries, SMT on its equity raise from Morgan Stanley Private Equity, Astec LifeSciences on the sale of equity to Godrej Agrovet and Nihon Nohyaku on its acquisition of Hyderabad Chemical Limited amongst others.

Sanjay holds an MBA from IIM Bangalore and a B Tech from IIT BHU.